FTC says PBMs ‘exercise vast control’ over healthcare, but stops short of calling for antitrust action

Drew Armstrong

Executive Editor

Federal antitrust regulators issued a report describing the PBM industry as highly concentrated among a handful of companies that use their market power to put …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FTC says PBMs ‘exercise vast control’ over healthcare, but stops short of calling for antitrust action

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Vertex gets January decision date for non-opioid pain medicine

Imunon shares up over 150% as ovarian cancer treatment extends survival in Phase 2

BioNTech, Regeneron claim Phase 2 win for cancer vaccine, PD-1 combo

After a year of tumult, Pfizer manages to pull off a boring quarter

Incyte drops four early-stage programs from its pipeline as part of strategic review

Hybrid Clinical Trials: Changing the dynamic and building a more efficient trial ecosystem.

FTC says PBMs ‘ex­er­cise vast con­trol’ over health­care, but stops short of call­ing for an­titrust ac­tion

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Ver­tex gets Jan­u­ary de­ci­sion date for non-opi­oid pain med­i­cine

Imunon shares up over 150% as ovar­i­an can­cer treat­ment ex­tends sur­vival in Phase 2

BioN­Tech, Re­gen­eron claim Phase 2 win for can­cer vac­cine, PD-1 com­bo

Af­ter a year of tu­mult, Pfiz­er man­ages to pull off a bor­ing quar­ter

In­cyte drops four ear­ly-stage pro­grams from its pipeline as part of strate­gic re­view

Hy­brid Clin­i­cal Tri­als: Chang­ing the dy­nam­ic and build­ing a more ef­fi­cient tri­al ecosys­tem.

FTC says PBMs ‘exercise vast control’ over healthcare, but stops short of calling for antitrust action

Vertex gets January decision date for non-opioid pain medicine

Imunon shares up over 150% as ovarian cancer treatment extends survival in Phase 2

BioNTech, Regeneron claim Phase 2 win for cancer vaccine, PD-1 combo

After a year of tumult, Pfizer manages to pull off a boring quarter

Incyte drops four early-stage programs from its pipeline as part of strategic review

Hybrid Clinical Trials: Changing the dynamic and building a more efficient trial ecosystem.